Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Net Cash Flow rose 172.41% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 125.51%. This contributed to the annual value of $52.5 million for FY2024, which is 2866.70% up from last year.
  • Latest data reveals that Silence Therapeutics reported Net Cash Flow of $40.4 million as of Q3 2025, which was up 272.96% from -$23.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Net Cash Flow registered a high of $74.0 million during Q1 2024, and its lowest value of -$56.7 million during Q1 2025.
  • Moreover, its 3-year median value for Net Cash Flow was -$9.1 million (2023), whereas its average is $785,541.
  • Examining YoY changes over the last 5 years, Silence Therapeutics' Net Cash Flow showed a top increase of 16,706.50% in 2022 and a maximum decrease of 1,253.11% in 2022.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Net Cash Flow stood at $3.0 million in 2021, then crashed by 1,253.11% to -$34.9 million in 2022, then skyrocketed by 72.37% to -$9.6 million in 2023, then surged by 499.44% to $38.5 million in 2024, then soared by 172.41% to $40.4 million in 2025.
  • Its Net Cash Flow was $40.4 million in Q3 2025, compared to -$23.4 million in Q2 2025 and -$56.7 million in Q1 2025.